Home/Filings/4/0001567619-22-008613
4//SEC Filing

Sullivan Lara 4

Accession 0001567619-22-008613

CIK 0001782223other

Filed

Apr 14, 8:00 PM ET

Accepted

Apr 15, 7:56 PM ET

Size

5.4 KB

Accession

0001567619-22-008613

Insider Transaction Report

Form 4
Period: 2022-04-14
Sullivan Lara
DirectorPresident ,CEO & CMO
Transactions
  • Award

    Common Stock

    2022-04-14+315,2731,356,636 total
Footnotes (3)
  • [F1]Represents restricted stock units ("RSUs") that vest on April 13, 2023, subject to the Reporting Person's continued employment through the vesting date.
  • [F2]The Compensation Committee also approved a grant to the Reporting Person, effective January 3, 2023, of an additional 95,684 RSUs that vest on April 13, 2023, subject to the Reporting Person's continued employment through the grant and vesting dates.
  • [F3]The Compensation Committee also approved a grant to the Reporting Person of $200,000 cash compensation that is payable in full on April 13, 2023, subject to the Reporting Person's continued employment through the payment date.

Documents

1 file

Issuer

Pyxis Oncology, Inc.

CIK 0001782223

Entity typeother

Related Parties

1
  • filerCIK 0001769457

Filing Metadata

Form type
4
Filed
Apr 14, 8:00 PM ET
Accepted
Apr 15, 7:56 PM ET
Size
5.4 KB